查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1378801

非黑色素瘤皮肤癌治疗市场：2023-2028 年全球产业趋势、份额、规模、成长、机会与预测

Non-Melanoma Skin Cancer Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3个工作天内

价格

抽象的

2022年，全球非黑色素瘤皮肤癌治疗市场规模达到5.354亿美元。展望未来， IMARC Group预计到2028年该市场将达到7.257亿美元，2022-2028年复合年增长率（CAGR）为5.2%。

非黑色素瘤皮肤癌（NMSC）是指皮肤上层恶性细胞的异常生长。 NMSC 的一些常见类型包括基底细胞癌、默克尔细胞癌和鳞状细胞癌以及皮肤 T 细胞淋巴瘤。它的主要特征是皮肤上出现坚硬的肿块或鳞状斑块。治疗方法包括透过外科手术去除癌细胞，包括显微手术、雷射疗法和冷冻疗法，以及各种非手术治疗，例如光动力疗法（PDT）、放射疗法和电疗法。

全球皮肤癌盛行率的增加和老年人口的增加是推动市场成长的关键因素。此外，大众对 NMSC 可用治疗替代方案的认识不断提高也刺激了市场成长。与传统使用的疗法相比，浅层放射疗法减少了对患者身体的副作用，并且可以透过创新的便携式设备进行。这些设备也用于高精度和高灵敏度的皮肤病变的早期诊断。此外，各种技术进步，例如电子近距离放射治疗（eBx）的发展，也是其他生长诱导因素。 eBx 是一种无痛、非侵入性的标靶低能量放射治疗，需要更短的治疗疗程，并将附近健康组织的辐射暴露风险降至最低。其他因素，包括个人医疗保健支出的增加和政府对临床试验的资助，以及广泛的研发（R＆D）活动，预计将进一步推动市场。

本报告回答的关键问题：

  • 迄今为止，全球非黑色素瘤皮肤癌治疗市场表现如何，未来几年将如何表现？
  • COVID-19 对全球非黑色素瘤皮肤癌治疗市场有何影响？
  • 主要区域市场有哪些？
  • 根据治疗类型的市场划分是怎样的？
  • 根据指示，市场的细分是什么？
  • 根据最终用途分類的市场是怎样的？
  • 产业价值链的各个阶段是什么？
  • 该行业的关键驱动因素和挑战是什么？
  • 全球非黑色素瘤皮肤癌治疗市场的结构如何？谁是主要参与者？
  • 产业竞争程度如何？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球非黑色素瘤皮肤癌治疗市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：按治疗类型分類的市场区隔

  • 化疗
    • 市场走向
    • 市场预测
  • 放射治疗
    • 市场走向
    • 市场预测
  • 光动力疗法
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：按迹象分類的市场

  • 基底细胞癌
    • 市场走向
    • 市场预测
  • T细胞淋巴瘤
    • 市场走向
    • 市场预测
  • 鳞状细胞癌
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：依最终用途分類的市场区隔

  • 医院
    • 市场走向
    • 市场预测
  • 专科诊所
    • 市场走向
    • 市场预测
  • 门诊手术中心
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：按地区分類的市场区隔

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太地区
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 按国家/地区分類的市场细分
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Accuray Incorporated
    • Almirall SA
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Elekta AB
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Icad Inc.
    • Merck & Co. Inc.
    • Novartis AG
    • Sun Pharmaceutical Industries Limited
    • Varian Medical Systems Inc.
Product Code: SR112023A3438

Abstract

The global non-melanoma skin cancer treatment market size reached US$ 535.4 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 725.7 Million by 2028, exhibiting a growth rate (CAGR) of 5.2% during 2022-2028.

Non-melanoma skin cancer (NMSC) refers to the abnormal growth of malignant cells in the upper layer of the skin. Some of the common types of NMSC include basal cell, merkle cell and squamous cell carcinoma and cutaneous T-cell lymphoma. It is primarily characterized by the development of firm lumps or scaly patches on the skin. The treatment methodologies involve the removal of cancer cells through surgical procedures, including micrographic surgery, laser therapy and cryotherapy, and various non-surgical treatments, such as photodynamic therapy (PDT), radiotherapy and electrotherapy.

The increasing prevalence of skin cancer and the rising geriatric population across the globe, represent as the key factors driving the growth of the market. Furthermore, rising awareness among the masses regarding the available treatment alternatives for NMSC is also stimulating the market growth. In comparison to the traditionally used therapies, superficial radiation therapy has reduced side-effects on the patient's body and can be conducted through innovative portable devices. These devices are also used for early diagnosis of skin lesions with high accuracy and sensitivity. Additionally, various technological advancements, such as the development of electronic brachytherapy (eBx), are acting as other growth-inducing factors. eBx is a painless and non-invasive targeted low-energy radiation therapy that requires a shorter treatment course and minimizes the risks of radiation exposure to the nearby healthy tissues. Other factors, including rising healthcare expenditures of individuals and government funding for clinical trials, along with extensive research and development (R&D) activities, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global non-melanoma skin cancer treatment market report, along with forecasts at the global, regional and country levels from 2023-2028. Our report has categorized the market based on treatment type, indication and end use.

Breakup by Treatment Type:

Chemotherapy

Radiation Therapy

Photodynamic Therapy

Others

Breakup by Indication:

Basal Cell Carcinoma

T-Cell Lymphoma

Squamous Cell Carcinoma

Others

Breakup by End Use:

Hospitals

Specialty Clinics

Ambulatory Surgery Centers

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Accuray Incorporated, Almirall S.A., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Elekta AB, Eli Lilly and Company, F. Hoffmann-La Roche AG, Icad Inc., Merck & Co. Inc., Novartis AG, Sun Pharmaceutical Industries Limited and Varian Medical Systems Inc.

Key Questions Answered in This Report:

  • How has the global non-melanoma skin cancer treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global non-melanoma skin cancer treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the treatment type?
  • What is the breakup of the market based on the indication?
  • What is the breakup of the market based on the end use?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global non-melanoma skin cancer treatment market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Non-Melanoma Skin Cancer Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Chemotherapy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Radiation Therapy
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Photodynamic Therapy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Basal Cell Carcinoma
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 T-Cell Lymphoma
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Squamous Cell Carcinoma
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End Use

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Specialty Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Ambulatory Surgery Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Accuray Incorporated
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Almirall S.A.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Boehringer Ingelheim GmbH
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 Bristol-Myers Squibb Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Elekta AB
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Eli Lilly and Company
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 F. Hoffmann-La Roche AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 SWOT Analysis
    • 14.3.8 Icad Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Merck & Co. Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Novartis AG
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Sun Pharmaceutical Industries Limited
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Varian Medical Systems Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Non-Melanoma Skin Cancer Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017-2022
  • Figure 3: Global: Non-Melanoma Skin Cancer Treatment Market: Breakup by Treatment Type (in %), 2022
  • Figure 4: Global: Non-Melanoma Skin Cancer Treatment Market: Breakup by Indication (in %), 2022
  • Figure 5: Global: Non-Melanoma Skin Cancer Treatment Market: Breakup by End Use (in %), 2022
  • Figure 6: Global: Non-Melanoma Skin Cancer Treatment Market: Breakup by Region (in %), 2022
  • Figure 7: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 8: Global: Non-Melanoma Skin Cancer Treatment (Chemotherapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Non-Melanoma Skin Cancer Treatment (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Non-Melanoma Skin Cancer Treatment (Radiation Therapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Non-Melanoma Skin Cancer Treatment (Radiation Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Non-Melanoma Skin Cancer Treatment (Photodynamic Therapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Non-Melanoma Skin Cancer Treatment (Photodynamic Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Non-Melanoma Skin Cancer Treatment (Other Treatment Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Non-Melanoma Skin Cancer Treatment (Other Treatment Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Non-Melanoma Skin Cancer Treatment (Basal Cell Carcinoma) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Non-Melanoma Skin Cancer Treatment (Basal Cell Carcinoma) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Non-Melanoma Skin Cancer Treatment (T-Cell Lymphoma) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Non-Melanoma Skin Cancer Treatment (T-Cell Lymphoma) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Non-Melanoma Skin Cancer Treatment (Squamous Cell Carcinoma) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Non-Melanoma Skin Cancer Treatment (Squamous Cell Carcinoma) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Non-Melanoma Skin Cancer Treatment (Other Indications) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Non-Melanoma Skin Cancer Treatment (Other Indications) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Non-Melanoma Skin Cancer Treatment (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Non-Melanoma Skin Cancer Treatment (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Non-Melanoma Skin Cancer Treatment (Specialty Clinics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Non-Melanoma Skin Cancer Treatment (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Global: Non-Melanoma Skin Cancer Treatment (Ambulatory Surgery Centers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Global: Non-Melanoma Skin Cancer Treatment (Ambulatory Surgery Centers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Global: Non-Melanoma Skin Cancer Treatment (Other End Uses) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Global: Non-Melanoma Skin Cancer Treatment (Other End Uses) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: North America: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: North America: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: United States: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: United States: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: Canada: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: Canada: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Asia Pacific: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Asia Pacific: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: China: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: China: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Japan: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Japan: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: India: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: India: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: South Korea: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: South Korea: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Australia: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Australia: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Indonesia: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Indonesia: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Others: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Others: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Europe: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Europe: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Germany: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Germany: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: France: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: France: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: United Kingdom: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: United Kingdom: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Italy: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Italy: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Spain: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Spain: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Russia: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Russia: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Others: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Others: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Latin America: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Latin America: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Brazil: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Brazil: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Mexico: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Mexico: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Others: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 77: Others: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 78: Middle East and Africa: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 79: Middle East and Africa: Non-Melanoma Skin Cancer Treatment Market: Breakup by Country (in %), 2022
  • Figure 80: Middle East and Africa: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 81: Global: Non-Melanoma Skin Cancer Treatment Industry: SWOT Analysis
  • Figure 82: Global: Non-Melanoma Skin Cancer Treatment Industry: Value Chain Analysis
  • Figure 83: Global: Non-Melanoma Skin Cancer Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Non-Melanoma Skin Cancer Treatment Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Breakup by Treatment Type (in Million US$), 2023-2028
  • Table 3: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Breakup by Indication (in Million US$), 2023-2028
  • Table 4: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Breakup by End Use (in Million US$), 2023-2028
  • Table 5: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Non-Melanoma Skin Cancer Treatment Market Structure
  • Table 7: Global: Non-Melanoma Skin Cancer Treatment Market: Key Players